Friday, July 10, 2026

Drug profile · INN

isoproterenol sulfate

isoproterenol sulfate (MEDIHALER-ISO) is a adrenergic receptor beta agonist. Route of administration: inhalation. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — isoproterenol sulfate
US status
approved
Class
Route
INHALATION
Patents
0
Programs
0
Data quality
0.84

Quick answer

isoproterenol sulfate (MEDIHALER-ISO) is a adrenergic receptor beta agonist. Route of administration: inhalation. Current US regulatory status: approved.

Key facts

INN isoproterenol sulfate
Brand MEDIHALER-ISO
Mechanism Adrenergic receptor beta agonist
Target Adrenergic receptor beta
Route INHALATION
Formulation AEROSOL, METERED

Mechanism of action

Adrenergic receptor beta agonist

Primary target: Adrenergic receptor beta

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. isoproterenol hydrochloride Adrenergic receptor beta agonist
  2. carteolol hydrochloride Adrenergic receptor beta antagonist

Frequently asked questions

What is isoproterenol sulfate?

isoproterenol sulfate (MEDIHALER-ISO) is a adrenergic receptor beta agonist. Route of administration: inhalation. Current US regulatory status: approved.

What is the brand name for isoproterenol sulfate?

MEDIHALER-ISO is a marketed brand name for isoproterenol sulfate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of isoproterenol sulfate?

isoproterenol sulfate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.